✦ LIBER ✦

14 A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)

✍ Scribed by N. Calvani; M.C. Chetri; M. Cinefra; M. D'Amico; P. Fedele; M. Marino; E. Mazzoni; A. Nacci; L. Orlando; P. Rizzo; P. Schiavone; F. Sponziello; S. Cinieri

Book ID: 117487914
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 46 KB
Volume: 36
Category: Article
ISSN: 0305-7372
DOI: 10.1016/s0305-7372(10)70040-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential Use of the Tyrosine Kinase In

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

✍ Christian Eichelberg; Roman Heuer; Felix K. Chun; Kristin Hinrichs; Mario Zachar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 326 KB

725 SEQUENTIAL USE OF MTOR -INHIBITORS I

725 SEQUENTIAL USE OF MTOR -INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

✍ J. Busch; C. Kempkensteffen; V. Grünwald; L. Weinkauf; S. Hinz; A. Magheli; K. M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 176 KB

95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM)

95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

✍ S. Weikert; C. Kempkensteffen; K. Zimmermann; V. Grünwald; A. Floercken; J. West 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 81 KB

PCN75 Survival and Costs in Metastatic R

PCN75 Survival and Costs in Metastatic Renal Cell Carcinoma: A Comparison of mRCC Treatment Pre- and Post Tyrosine Kinase Inhibitor (TKI) Introduction Using Retrospective Registry Data

✍ L. Jönsson; R. Sandin; P. Lindgren; J. Kowalski; T. Wahlgren; U. Harmenberg; P. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

252 RETROSPECTIVE ANALYSIS OF THE SEQUEN

252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)

✍ C. Porta; G. Procopio; R. Sabbatini; A. Bearz; I. Chiappino; I. Imarisio; V. Gua 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 517 KB

7131 POSTER Optimizing the Sequencial Tr

7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib

✍ Porta, C.; Paglino, C.; Procopio, G.; Sabbatini, R.; Bellmunt, J.; Schmidinger, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB